Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention

Summary

This study is a single site double blinded Phase II study to evaluate the chemopreventative effectiveness of vismodegib in the treatment of subjects at high risk for developing basal cell carcinomas (BCC).

Timeline

Start

2014-02-17

Primary completion

2016-12-31

Completion

2016-12-31

Outcome

Outcome not reported

Stopped (Enrollment): “Low enrollment”

Drugs

Indications